Overview

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Status:
Active, not recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with select advanced malignancies.
Phase:
Phase 1
Details
Lead Sponsor:
Incyte Corporation
Treatments:
Immunoglobulins